Send us Feedback

NeurogesX (NGSX)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
Benzinga's Microcap Movers for Wednesday April 11, 2012
Benzinga  Apr 12  Comment 
Below are highlights from Benzinga's daily coverage of microcap securities making big moves: NeurogesX Shares of NeurogesX (NASDAQ: NGSX), the San Mateo, CA biopharmaceutical company, rose 22% Wednesday on twice the average daily...
NeurogesX (NGSX) Gets FDA Acceptance for End-of-Phase 2 Meeting for NGX-1998
StreetInsider.com  Apr 11  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/NeurogesX+%28NGSX%29+Gets+FDA+Acceptance+for+End-of-Phase+2+Meeting+for+NGX-1998/7336831.html for the full story.
NeurogesX Provides Update on NGX-1998 Clinical Program
Globe Newswire  Apr 11  Comment 
SAN MATEO, Calif., April 11, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today announced that the
Neurogesx (NGSX) Files 2.97M Common Shelf for Shareholders
StreetInsider.com  Mar 29  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/Neurogesx+%28NGSX%29+Files+2.97M+Common+Shelf+for+Shareholders/7307664.html for the full story.
NeurogesX slashes staff, shifts R&D direction after FDA slaps down app
FierceBiotech  Mar 8  Comment 
As expected, the FDA has rejected NeurogesX's application to expand the use of Qutenza, which clearly came as no surprise to management. After getting raked over the coals by regulators and then unanimously voted down by an expert panel, which...
NeurogesX (NGSX) Tops Q4 EPS by 7c; Announces Restructuring, Cutting 43 Jobs; Received CRL, FDA Seeking Added Data from Qutenza Trials
StreetInsider.com  Mar 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/NeurogesX+%28NGSX%29+Tops+Q4+EPS+by+7c%3B+Announces+Restructuring%2C+Cutting+43+Jobs%3B+Received+CRL%2C+FDA+Seeking+Added+Data+from+Qutenza+Trials/7251935.html for the full story.
NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Full Year 2011 Results
Globe Newswire  Feb 29  Comment 
SAN MATEO, Calif., Feb. 29, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today announced it will hold
NeurogesX slammed again as FDA panel spurns pain patch
FierceBiotech  Feb 10  Comment 
NeurogesX ($NGSX) finds itself on the ropes this morning, with its badly battered shares taking yet another beating after an FDA panel unanimously shot down an attempt to get an approval to use its pain patch for HIV-related neuropathy. Earlier...
After-Hours Movers 02/09: (SWIR) (LNKD) (UEPS) Higher; (NGSX) (XIDE) (TRLG) (NUAN) Lower
StreetInsider.com  Feb 9  Comment 
NeurogesX (Nasdaq: NGSX) 25% LOWER; today announced that the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) to the U.S. FDA did not recommend FDA approval of a new indication for Qutenza® (Capsaicin) 8% patch for the...




more ▼WIKI ANALYSIS
 The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.


 




References

Retrieved from "http://www.wikinvest.com/stock/NeurogesX_(NGSX)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki